



HAL
open science

The steroid derivative 6-aminocholestanol inhibits the DEAD-box helicase eIF4A (LieIF4A) from the Trypanosomatid parasite Leishmania by perturbing the RNA and ATP binding sites

Yosser Zina Abdelkrim, Emna Harigua-Souiai, Mourad Barhoumi, Josette Banroques, Arnaud Blondel, Ikram Guizani, N. Kyle Tanner

► To cite this version:

Yosser Zina Abdelkrim, Emna Harigua-Souiai, Mourad Barhoumi, Josette Banroques, Arnaud Blondel, et al.. The steroid derivative 6-aminocholestanol inhibits the DEAD-box helicase eIF4A (LieIF4A) from the Trypanosomatid parasite Leishmania by perturbing the RNA and ATP binding sites. *Molecular and Biochemical Parasitology*, 2018, 226, pp.9-19. 10.1016/j.molbiopara.2018.10.001 . pasteur-02528567

HAL Id: pasteur-02528567

<https://pasteur.hal.science/pasteur-02528567>

Submitted on 1 Apr 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **The steroid derivative 6-aminocholestanol inhibits the DEAD-box helicase**
2 **eIF4A (LieIF4A) from the Trypanosomatid parasite *Leishmania* by**
3 **perturbing the RNA and ATP binding sites**
4
5
6
7

8 Yosser Zina Abdelkrim^{1,2,3}, Emna Harigua-Souiai², Mourad Barhoumi², Josette Banroques¹,
9 Arnaud Blondel⁴, Ikram Guizani^{2*}, N. Kyle Tanner^{1*}

10
11
12
13 ¹ Expression Génétique Microbienne, CNRS UMR8261/Université Paris Diderot-Paris 7 &
14 Paris Sciences et Lettres Research University, Institut de Biologie Physico-Chimique, 13 rue
15 Pierre et Marie Curie, 75005 Paris, France

16
17 ² Molecular Epidemiology and Experimental Pathology (LR16IPT04), Institut Pasteur de
18 Tunis/Université de Tunis el Manar, 13 Place Pasteur, BP74 Tunis-Belvédère, 1002 Tunisia

19
20 ³ Faculté des Sciences de Bizerte, Université de Carthage, 7021 Zarzouna-Bizerte, Tunisia.

21
22 ⁴ Unité de Bioinformatique Structurale, CNRS UMR 3528, Département de Biologie
23 Structurale et Chimie, Institut Pasteur, 25-28 rue du Dr Roux, 75015 Paris, France.

24
25
26
27
28
29 * Corresponding author.

30 *E-mail address:* kyle.tanner@ibpc.fr (N.K. Tanner)

31 CNRS UMR8261, IBPC, 13 rue Pierre et Marie Curie, 75005, Paris, France

32
33 * Correspondence can also made to:

34 *E-mail address:* ikram.guizani@pasteur.ms.tn (I. Guizani)

35 Molecular Epidemiology and Experimental Pathology (LR16IPT04), Institut Pasteur de
36 Tunis/Université de Tunis el Manar, 13 Place Pasteur, BP74 Tunis-Belvédère, 1002 Tunisia

37
38
39
40
41 **Abbreviations:** ATP, adenosine 5'-triphosphate; BSA, bovine serum albumin; CL, cutaneous
42 leishmaniasis;; DMSO, dimethyl sulfoxide; eIF4A_{Mus}, mouse translation initiation factor
43 eIF4AI; EDTA, ethylenediaminetetraacetic acid; Gp32, bacteriophage T4 gene 32; LieIF4A,
44 *L. infantum* translation initiation factor 4A;; RecA, recombinant protein A;; Tris-HCl,
45 Tris(hydroxymethyl)aminomethane hydrochloride; VL, visceral leishmaniasis.
46
47

1 **Abstract**

2 The antifungal agent 6-aminosterol targets the production of ergosterol, which is the
3 principle sterol in many fungi and protozoans; ergosterol serves many of the same roles as
4 cholesterol in animals. We found that it also is an effective inhibitor of the translation-
5 initiation factor eIF4AI from mouse (eIF4AI_{Mus}) and the Trypanosomatid parasite *Leishmania*
6 (*LieIF4A*). The eIF4A proteins belong to the DEAD-box family of RNA helicases, which are
7 ATP-dependent RNA-binding proteins and RNA-dependent ATPases. DEAD-box proteins
8 contain a commonly-shared core structure consisting of two linked domains with structural
9 homology to that of recombinant protein A (RecA) and that contain conserved motifs that are
10 involved in RNA and ATP binding, and in the enzymatic activity. The compound inhibits
11 both the ATPase and helicase activities by perturbing ATP and RNA binding, and it is
12 capable of binding other proteins containing nucleic acid-binding sites as well. We undertook
13 kinetic analyses and found that the *Leishmania* *LieIF4A* protein binds 6-aminosterol
14 with a higher apparent affinity than for ATP, although multiple binding sites were probably
15 involved. Competition experiments with the individual RecA-like domains indicate that the
16 primary binding sites are on RecA-like domain 1, and they include a cavity that we previously
17 identified by molecular modeling of *LieIF4A* that involve conserved RNA-binding motifs.
18 The compound affects the mammalian and *Leishmania* proteins differently, which indicates
19 the binding sites and affinities are not the same. Thus, it is possible to develop drugs that
20 target DEAD-box proteins from different organisms even when they are implicated in the
21 same biological process.

22

23

24

25

26 **Keywords** (5): *Leishmania infantum*; drug design; hippuristanol; RNA helicase; translation-
27 initiation factor

28

29

1 **1. Introduction**

2 Leishmaniasis are neglected tropical diseases caused by the Trypanosomatid parasite
3 *Leishmania* that affect mostly developing countries with limited public health resources. Each
4 year it is estimated that there are around 0.7 to 1.2 million new cases of cutaneous
5 leishmaniasis (CL) and about 0.2 to 0.4 million new cases of the most severe form of the
6 disease, visceral leishmaniasis (VL), which is typically fatal if left untreated [1].
7 Leishmaniasis require adequate control measures, clinical vaccines and effective drug
8 treatments. The current drug treatment regimens for leishmaniasis have recently been reviewed
9 [3]. They include liposomal amphotericin B (LAMB), pentavalent antimonials monotherapy
10 and pentavalent antimonials in combination with topical agents, such as paromomycin for
11 VL/CL, pentoxifylline or allopurinol for CL and pentoxifylline for mucocutaneous
12 leishmaniasis (MCL). Other systemic mono-therapies are recommended such as miltefosine
13 for VL/CL or pentamidine for CL/MCL. Moreover, alternative combination regimens are
14 available for CL and VL. However, these drugs are expensive and are often associated with
15 toxicities and adverse side effects. Moreover, there is the risk of the parasites developing drug
16 resistance. Effective vaccines against *Leishmania* are still under development [4]. Thus, there
17 is an urgent need to develop more selective, less expensive new drugs. In this vein, we are
18 interested in finding inhibitors of the DEAD-box helicases from *Leishmania*.

19 DEAD-box helicases are ubiquitous proteins that are associated with all processes
20 involving RNA, from transcription, processing, transport, translation and to RNA decay [5,
21 6]. They are ancestral proteins that are found in all three kingdoms of life. *In vitro*, the
22 characterized proteins are ATP-dependent RNA-binding proteins and RNA-dependent
23 ATPases. Moreover, they have been shown to disrupt short RNA-RNA and RNA-DNA
24 duplexes, albeit inefficiently [6, 7]. *In vivo*, DEAD-box proteins are highly specific and
25 highly regulated; specificity is probably conferred by the cellular context and associated

1 cofactors [8]. Their importance to the cell is indicated by the large number of variants DEAD-
2 box proteins. For example, the yeast *Saccharomyces cerevisiae* has 25 different DEAD-box
3 helicases that are mostly essential and rarely interchangeable [9]. Humans have 36 different
4 proteins and *L. major* has 28 [10, 11].

5 The DEAD-box proteins are characterized by conserved core structures consisting of
6 two linked domains with structural homology with that of recombinant protein A (RecA). The
7 RecA-like domains contain eleven conserved motifs that are involved in ATP and RNA
8 binding, and in the enzymatic activity [6, 7, 12]. The Q motif is involved in adenine
9 recognition; motifs Ia, GG, Ib, IV, QxxR and V bind the RNA; and motifs I (Walker A
10 motif), II (Walker B motif), III, V and VI interact with the phosphoanhydride backbone of the
11 ATP. Binding of ATP and RNA promote a "closed" conformation of the two RecA-like
12 domains, which has a high affinity for the ligands. Hydrolysis of the ATP and subsequent
13 phosphate release promotes an "open" conformation where the RecA-like domains are not
14 constrained relative to one another and that have low affinity for the RNA. In addition,
15 DEAD-box proteins have variable amino- and carboxyl-terminal extensions, as well as
16 insertions and deletions within the core domains.

17 Because of their important cellular roles, these helicases are potential targets for
18 therapeutic and prophylactic agents [13-16]. The mammalian DEAD-box proteins eIF4AI and
19 eIF4AII, which are translation-initiation factors, have been of particular interest for screening
20 for candidate drugs [17]. One such compound is hippuristanol. Hippuristanol is a
21 hydroxycholestanol (a steroid derivative) isolated from the coral *Isis hippuris* [18]. It is an
22 allosteric inhibitor of RNA binding to eIF4A most likely by locking the two RecA-like
23 domains in an aberrant closed conformation [19]. The proposed binding site encompasses and
24 extends beyond motifs V and VI, and it is thought to be unique to eIF4A-like proteins; as a
25 consequence, it shows little inhibition of other tested DEAD-box proteins [19].

1 We previously showed that LieIF4A (*LinJ01.0780/LinJ01.0790*) was a probable
2 ortholog of eIF4A in *L. infantum* (a causal species of visceral leishmaniasis), which was
3 consistent with the results of others [20-22]. We subsequently used molecular modeling,
4 molecular dynamics and docking simulations of LieIF4A to identify potential drug targets on
5 the protein, and then we screened potential candidates for these sites through an analysis of
6 the RNA-dependent ATPase activity [23]. The various compounds inhibit both LieIF4A and
7 mouse eIF4AI (eIF4AI_{Mus}), although we noted that there are significant differences in the
8 enzymatic properties. We found that the epimeric compound 6- α/β -aminocholestanol is of
9 particular interest; the data are consistent with it binding the RecA-like domain 1 of LieIF4A
10 at a pocket consisting of the RNA-interacting motifs Ia, GG and Ib, and a short three-amino-
11 acid insertion that was absent in the alignments of other DEAD-box proteins [23]. The pocket
12 is predicted to exist only in the open conformation of the RecA-like domains, which exhibits
13 more conformational flexibility. This result is noteworthy because the compound has
14 significant structural similarity to hippuristanol even though the initial screening of
15 compounds was constrained only for sites detected through the modeling. We validated the 6-
16 aminocholestanol with experimental assays on extracellular promastigotes (IC₅₀ = 4.1 μ M)
17 and on intramacrophage amastigotes (IC₅₀ = 1.4 μ M); it showed little toxicity on the host cell
18 (CC₅₀ = 43.4 μ M). Thus, 6-aminocholestanol exhibited a selectivity index of 31.7, which
19 makes it a promising anti-*Leishmania* molecule [23].

20 In this study, we have further characterized the effects of 6-aminocholestanol on
21 LieIF4A, and we have made additional comparisons between LieIF4A and eIF4AI_{Mus}. Both
22 the *Leishmania* and mouse proteins are sensitive to the compound but in different ways; we
23 find that the inhibitory effects probably involve different binding pockets on the two proteins.
24 This indicates that in principle drugs can specifically target DEAD-box proteins with the

1 same function from different organisms, which is desirable for the selective treatment of
2 parasitic infections such as Leishmaniasis.

3

4 **2. Materials and methods**

5 *2.1. Compounds and proteins*

6 A limited amount of the isomeric 6-aminocholestanol was obtained directly from the
7 synthesizing laboratory [24]. It consisted of a mix of 84% 6- α -aminocholestanol and 16% 6-
8 β -aminocholestanol. We previously showed that the pure epimer 6- α -aminocholestanol gave
9 similar results [23]. The compound was dissolved in ultrapure anhydrous DMSO (D2650;
10 Sigma-Aldrich, St. Louis, MO, USA) to make stock solutions. Solutions were stored at -20°C
11 until needed. BSA and Gp32 were obtained from Sigma-Aldrich.

12

13 *2.2. Protein expression and purification*

14 The mutant RecA-like domain 1 (1–238; D1-GAT) was amplified from the previously
15 described K76A mutant of Lief4A and domain 1 oligonucleotides [20, 25]. In brief, the gene
16 was amplified with oligonucleotides Lief2_up (5' GCG CGA CTA GTC ATA TGG CGC
17 AGA ATG ATA AGA TCG 3'), which contained SpeI and NdeI sites, and LiefD1_3' (5'
18 GCG CGC TCG AGC GTC AGG CTC TCG CGC TTC 3'), which contained an XhoI site;
19 regions of hybridization are shown underlined. The product was digested with NdeI and XhoI,
20 purified by electrophoretic separation on a 1% agarose gel and eluted, and then it was cloned
21 into the pET-22b (Merck-Novagen, Darmstadt, Germany) expression vector digested with the
22 same enzymes. The final construct was verified by sequencing.

23 The mouse eIF4AI gene (*DDX2A*; P60843) was a gift from Patrick Linder [26]. It was
24 similarly PCR amplified with oligonucleotides IF41_Mus_up (5' GCG CGA CTA GTC ATA
25 TGT CTG CGA GTC AGG ATT CT 3') and IF41_Mus_low (5' GCG CGC TCG AGA ATG

1 AGG TCA GCA ACG TTG A 3') that contained the same restriction sites as described for
2 LieIF4A. Cloning into pET22b was as described above. The construction of the other
3 expression vectors for LieIF4A (1–403), LieIF4A RecA-like domain 1 (1–238; LieIF4A-D1)
4 and LieIF4A RecA-like domain 2 (239–403; LieIF4A-D2) was as previously described [20,
5 25].

6 The His6-tagged recombinant proteins were expressed in the Rosetta *Escherichia coli*
7 strain, and the proteins were purified as previously described [20, 23, 25]. In parallel,
8 catalytically inactivated proteins (GAT mutation of motif I) were purified to test for
9 contaminating ATPases; these proteins showed a background activity of only a few percent of
10 the wildtype proteins. Protein concentrations were determined by the Bio-Rad Protein Dye
11 assay using BSA as a standard. The purity and concentrations were verified by
12 electrophoretically separating the proteins on a 12% polyacrylamide Laemmli gel (Bio-Rad
13 Mini-Protean; Hercules, CA, USA) containing sodium dodecyl sulfate (SDS-PAGE), and the
14 proteins were visualized by staining the gels with Coomassie Brilliant Blue R-250. Purified
15 proteins were stored in 50% glycerol at -80 °C until needed.

16

17 2.3. ATPase assay

18 We used a colorimetric assay to measure the phosphate released during ATP
19 hydrolysis based on Malachite green as previously described [20]. The reaction buffers
20 contained 50 mM potassium acetate, 20 mM MES, pH 6, 2 mM dithiothreitol (DTT), 0.1
21 mg/mL BSA and various concentrations of whole yeast RNA (Type XI-C, Sigma-Aldrich).
22 We added 5 mM magnesium acetate to the LieIF4A reactions and 1 mM to those with
23 eIF4AI_{Mus}; mouse eIF4AI was inhibited by high Mg²⁺ concentrations while LieIF4A was
24 optimally active at the higher concentration [20]. Reactions were started by adding ATP and
25 then incubated at 37 °C for various times in 1.5 mL Eppendorf tubes. Then, 50 µL aliquots

1 were taken and pipetted into 96 well microtiter plates. Reactions were stopped by making the
2 solutions ~60 mM in ethylenediaminetetraacetic acid (EDTA). Each reaction was done in 50
3 μ L volumes. The absorption at 630 nm was converted to phosphate concentration by a
4 reference curve generated from a dilution series of a known phosphate concentration (0.1 mM
5 Pi standard; Innova Biosciences). Reaction velocities were determined by a linear regression
6 fit of the phosphate generated against time. Only the initial, linear phases of the curves were
7 used. Velocities were determined for at least three independent experiments for each reaction
8 condition. Data were analyzed with Kaleidagraph (Synergy).

9

10 2.4. RNA helicase activity

11 RNA helicase assays were similar to those previously described [27]. In brief, we used
12 a 45-nucleotide-long RNA (K06; 5' GGG CUA GCA CCG UAA AGC AAG UUA AUU
13 CAA AAC AAA ACA AAA GCU 3') that was transcribed *in vitro* by T7 RNA polymerase
14 off of a HindIII-linearized template using the MEGAshortscript kit (Ambion ThermoFisher
15 Scientific, Waltham, MA, USA). The RNA products were separated by electrophoresis on a
16 8% PAGE gel containing 7 M urea, and the band corresponding to the desired product was
17 eluted, extracted with phenol, extracted with chloroform-isoamyl alcohol (24:1) and ethanol
18 precipitated as previously described [28]. The centrifuged and dried pellet was resuspended in
19 20 mM Tris-HCl, pH 7.5, 0.1 mM EDTA and stored at -20 °C until needed. A 13-nucleotide-
20 long RNA oligonucleotide (Hyb13-RNA; 5' CUU UAC GGU GCU A 3'; Dharmacon/Thermo
21 Scientific, Lafayette, CO, USA) that was complementary to K06 was labeled at the 5' end
22 with γ -³²P-ATP (~3000 Ci/mmol; PerkinElmer, Waltham, MA, USA) and T4 polynucleotide
23 kinase (New England Biolabs, Ipswich, MA, USA) for 30 minutes at 37 °C, heat inactivated at
24 65 °C for 20 minutes, and stored at -20 °C until needed.

1 The duplex was made by incubating ³²P-Hyb13 RNA with K06 RNA at equimolar
2 concentrations in a solution containing 50 μM of each RNA, 200 mM potassium acetate 20
3 mM Tris-HCl, pH 8.0 and 0.1 mM EDTA. Annealing was accomplished with a MyCycler
4 PCR (Bio-Rad) by heating to 80 °C for 30 seconds, slow cooling to 50 °C and incubating for
5 30 minutes, slow cooling to 30 °C and incubating for another 30 minutes and finally slow
6 cooling to 4 °C. The duplex was subsequently extracted with phenol, extracted with
7 chloroform-isoamyl alcohol and ethanol precipitated. The centrifuged and dried pellet was
8 resuspended in a buffer containing 200 mM potassium acetate, 20 mM Tris-HCl, pH 7.5 and
9 0.1 mM EDTA at a duplex concentration of ~8 μM. The solution was incubated at 37 °C for 1
10 hour to ensure the duplex was equilibrated. Duplexes were stored at -20 °C until needed. The
11 duplex had a calculated Gibbs free energy of -18.8 kcal/mole (-78.7 J/mole) in 1 M NaCl at
12 37 °C, by using the published nearest-neighbor-free-energy values [29].

13 Assays were done under the same buffer conditions as those used for the ATPase
14 experiments. Reactions typically contained 50 nM of the ³²P-duplex, 1 mM ATP and 1 μM of
15 an 18-nucleotide-long DNA oligonucleotide that was complementary to Hyb13 (α-Hyb1; 5'
16 CTA GCA CCG TAA AGC AAG 3'). The 20-fold excess of α-Hyb1 oligonucleotide trapped
17 the released Hyb13 RNA during the reaction and prevented it from re-annealing on the K06
18 RNA. Various concentrations of proteins were tested but we typically used 200 to 250 nM
19 LieIF4A and 1000 nM eIF4A_{Mus}. The higher amount of eIF4A_{Mus} was needed to compensate
20 for its weaker helicase activity and to facilitate comparisons. Reactions were carried out at 37
21 °C for various times, the products were separated by electrophoresis on a 15%
22 polyacrylamide gel at 4 °C under non-denaturing conditions, and the corresponding bands
23 were quantified with an imaging plate (Fujifilm BAS-IP MS 2025) and a Typhoon FLA9500
24 (GE Healthcare) phosphoimager. Data were analyzed with Optiquant (Packard) and
25 Kaleidagraph software.

1

2 *2.5. Molecular modeling, molecular dynamics, cavity analysis and docking simulations*

3 We used two models of LieIF4A that corresponded to the ligand-free form ("open")
4 and ligand-bound form ("closed") that were constructed and subjected to 2 ns molecular
5 dynamics (MD) simulations as previously described [23]. We took 100 snapshots of their
6 trajectories to perform an exhaustive search of the cavities using an in-house software based
7 on Lee and Richards solvent accessible surface detection algorithm [30], called mkgridX [31].
8 The cavities for each snapshot structure were identified by clustering as previously described
9 [23]. Individual cavities less than 12 Å³, the volume of a water molecule, were discarded.
10 Cavities from different snapshots were clustered by protein contact similarity to define sites,
11 called P1, P2, etc. Likewise, cavities also were detected on solved crystal structures for the
12 human/mouse ortholog eIF4AI (DDX2A; PDB 3EIQ, chain D), the T4 bacteriophage Gp32
13 protein (PDB 1GPC) and bovine serum albumin (PDB 3V03, chains A, B).

14 Molecular docking of 6- α -aminocholestanol was performed with AutoDock 4.2 [32],
15 and we targeted all pockets identified on Gp32, DDX2A, BSA and on the 200 snapshots of
16 both conformations of LieIF4A. PDBQT files of the ligand and the receptors were prepared
17 using AutoDock Tools. One receptor file was generated per protein or snapshot by adding all
18 the hydrogen atoms, adding the Gasteiger atomic charges, deleting nonpolar hydrogens and
19 merging their charges with the carbon atoms, assigning atom types, detecting a root atom for
20 the torsion tree and finally defining the rotatable bonds. The grid maps required by AutoDock
21 were generated using AutoGrid [32] for each pocket by using the corresponding receptor file
22 and by focusing on the geometrical center of the pocket defined by the ensemble of its
23 residues. Point spacing was 0.375 Å. The Lamarckian Genetic algorithm of AutoDock 4 was
24 used for the conformation search step, and it was coupled to a clustering analysis step.

1 The docking poses with the lowest docking scores on each cavity were retained. Poses
2 with an estimated energy of binding higher than -6 kcal/mol were considered as
3 nonsignificant [33]. For the retained docking poses, we generated the corresponding
4 interaction diagrams using LigPlot+ with its default parameters [34]. Structures were
5 visualized and manipulated with Swiss-PDBViewer 4.1.0
6 (<http://www.expasy.org/spdbv/>)[35]. Protein surfaces with the electrostatic potentials were
7 done with the default settings.


8

9 **3. Results**

10 *3.1. 6-aminocholestanol competitively inhibits the ATPase activity*

11 We previously compared the ATPase activity of LieIF4A and eIF4AI_{Mus} and found
12 that 6-aminocholestanol inhibited both proteins to a similar extent [23]. In this work, we
13 undertook more extensive kinetic analyses of the mode of inhibition on LieIF4A. DEAD-box
14 proteins are RNA-dependent ATPases, so we determined the Michaelis–Menten parameters
15 with saturating concentrations of RNA in the absence or presence of different quantities of 6-
16 aminocholestanol (Fig. 1a). We obtained a K_m of $150 \pm 20 \mu\text{M}$ (standard error of the
17 regression) in the absence of the compound, which showed a higher binding affinity than
18 what we previously measured ($350 \mu\text{M}$) [20]. Similarly, the k_{cat} ($V_{\text{max}}/[\text{LieIF4A}]$) was $2.4 \pm$
19 0.1 min^{-1} , which was 2-fold higher than our previously measured value. This probably
20 reflected the different RNA substrates, protein preparations and particularly the presence of
21 DMSO.

22



1
 2 **Fig. 1.** ATPase reaction velocities of LieIF4A. The means and standard deviations are shown
 3 for three or more independent experiments. The values were fit to the nonlinear Michaelis–
 4 Menten equation $v = V_{\max}[S]/(K_m + [S])$, where $[S]$ is the substrate concentration, K_m is the
 5 Michaelis–Menten binding constant and V_{\max} the maximum reaction velocity, using
 6 Kaleidagraph software. All the reactions were done in the presence of 10% DMSO and 820
 7 nM LieIF4A. Red o, no added compound; blue □, 100 μM 6-aminocholestanol; green ◇, 300
 8 μM 6-aminocholestanol. (a) The reaction velocities of LieIF4A with 340 ng/μl RNA and
 9 different concentrations of ATP, in the presence or absence of 6-aminocholestanol, are as
 10 indicated. (b) The reaction velocities of LieIF4A with 5 mM ATP at different concentrations
 11 of whole yeast RNA in the presence or absence of 6-aminocholestanol.
 12

13 With the addition of 100 μM 6-aminocholestanol, the kinetic parameters were a K_m of
 14 $1100 \pm 200 \mu\text{M}$ and a k_{cat} of $2.5 \pm 0.2 \text{ min}^{-1}$ (Fig. 1a). This was initially perplexing because
 15 the pronounced increase in the K_m for ATP indicated that the compound was reducing the
 16 affinity of LieIF4A for ATP rather than for RNA, which would have been expected to affect
 17 the k_{cat} . Similarly, with 300 μM 6-aminocholestanol we obtained a K_m of $3700 \pm 2600 \mu\text{M}$
 18 and a k_{cat} of $1.2 \pm 0.4 \text{ min}^{-1}$ (Fig 1a). This measured weak binding affinity for ATP was near
 19 the limit of sensitivity of our experimental assay, and consequently the values showed much
 20 higher uncertainty. Nevertheless, the values were again consistent with the compound
 21 primarily weakening ATP binding.

22 The Lineweaver–Burke plot was consistent with competitive inhibition of ATP
 23 binding. We subsequently fit our data to various formulations of the Dixon plot [36]. There
 24 was significant variability in the data but we obtained an inhibition constant, K_i , of around 35

1 to 100 μM , which indicated a higher binding affinity for 6-aminocholestanol than for ATP.
2 Competitive inhibition was most consistent with the compound directly competing with ATP
3 for the binding site on the protein rather than blocking the RNA. However, it was previously
4 shown that ligands (RNA and ATP) show positive cooperative binding to eIF4A_{Mus} [37].
5 Consequently, it was possible that 6-aminocholestanol binding at the RNA site could alter the
6 affinity of the protein for ATP and consequently allosterically affect ATP binding. This
7 would be consistent with our molecular modeling studies that indicated that the binding site
8 exists only in the open conformation of the RecA-like domains [23]. Thus, the compound
9 might "lock" the protein in a conformation that had a low affinity for ligands.

10

11 *3.2. 6-aminocholestanol competitively inhibits RNA binding*

12 We initially tried electrophoretic mobility shift assays (EMSA)[38] with fluorescent-
13 labeled RNA oligonucleotides (5' Cy5-UCA UAC UUU UCU UUU CUU UUC CAU C-3') to
14 measure the effects of the compound on RNA binding. Unfortunately, the relatively weak
15 RNA binding and high protein concentrations that were needed gave a weak signal that was
16 not easy to interpret. Consequently, we used Michaelis–Menten kinetics to measure the
17 effects of varying the concentration of whole yeast RNA under saturating ATP concentrations
18 in the presence and absence of 6-aminocholestanol. There was experimental scatter, but the
19 data showed a good fit to the nonlinear Michaelis–Menten equation (Fig 1b). Again, the
20 compound primarily reduced the binding affinities (higher K_m) for RNA; the values for k_{cat}
21 were $2.3 \pm 0.1 \text{ min}^{-1}$ in the absence of compound, $1.9 \pm 0.1 \text{ min}^{-1}$ with 100 μM 6-
22 aminocholestanol and $0.71 \pm 0.09 \text{ min}^{-1}$ with 300 μM . The whole yeast RNA represented a
23 heterogeneous mix of substrates, and consequently the actual concentration of the RNA
24 substrates was unknown; thus we could only determine relative K_m values. We found that the
25 K_m for the RNA was increased 3.6 ± 0.7 -fold with 100 μM of the compound, which was

1 consistent with 6-aminocholestanol indirectly affecting ATP binding and catalysis by
 2 interfering with RNA binding, but the results were not conclusive.

3

4 3.3. 6-aminocholestanol binds to nucleic acid-binding proteins

5 In our initial modeling, molecular dynamics and docking simulations, 6-
 6 aminocholestanol bound in a pocket formed in the open conformation of the protein that
 7 consisted, in part, by RNA-interacting motifs Ia, GG and Ib, which are within RecA-like
 8 domain 1 [23]. If this were true, then domain 1 should bind the compound independently of
 9 the rest of the protein. We tested this by using the isolated RecA-like domain 1 as a
 10 competitor for compound binding in the ATPase assays. LieIF4A showed a reaction velocity
 11 of 1.89 $\mu\text{M}/\text{min}$ in the presence of RNA and 10% DMSO, which we defined as a relative
 12 activity of 100% (Table 1). LieIF4A had ~8% of the ATPase activity in the absence of RNA
 13 (0.16/1.89). The RNA-dependent ATPase activity was reduced nearly 8-fold by the presence
 14 of 300 μM 6-aminocholestanol (1.89/0.24; Table 1).

15

Table 1. The RNA-dependent ATPase activity.

Protein ^a	RNA ^b	6-NH-cholestanol ^c	V ($\mu\text{M}/\text{min}$) ^d	Relative ^e
LieIF4A	+	–	1.89 \pm 0.25	1.00 \pm 0.13
LieIF4A	–	–	0.16 \pm 0.02	0.08 \pm 0.01
LieIF4A	+	+	0.24 \pm 0.02	0.13 \pm 0.01
LieIF4A + D1	+	–	2.28 \pm 0.20	1.21 \pm 0.10
LieIF4A + D1	+	+	1.67 \pm 0.07	0.88 \pm 0.04
LieIF4A + D1-GAT	+	–	1.34 \pm 0.15	0.71 \pm 0.08
LieIF4A + D1-GAT	+	+	1.29 \pm 0.19	0.68 \pm 0.10
LieIF4A + D2	+	–	1.60 \pm 0.18	0.85 \pm 0.10
LieIF4A + D2	+	+	1.08 \pm 0.06	0.57 \pm 0.03
LieIF4A + Gp32	+	–	1.99 \pm 0.24*	1.05 \pm 0.13*
LieIF4A + Gp32	+	+	1.63 \pm 0.06	0.86 \pm 0.03
LieIF4A + BSA	+	–	1.72 \pm 0.13	0.91 \pm 0.07
LieIF4A + BSA	+	+	0.24 \pm 0.05*	0.13 \pm 0.02*
D1	–	–	0.16 \pm 0.04	0.08 \pm 0.02
D1	–	+	0.27 \pm 0.17	0.14 \pm 0.09
D1	+	–	0.40 \pm 0.17	0.21 \pm 0.09
D1	+	+	0.20 \pm 0.02	0.11 \pm 0.01
D1-GAT	+	–	0.18 \pm 0.09	0.10 \pm 0.05
D2	+	–	0.03 \pm 0.02	0.02 \pm 0.01

^a LieIF4A (1-403), 820 nM; D1, RecA-like domain 1 (1-238), 8.8 μM; D1-GAT, 8.7 μM; D2, RecA-like domain 2 (239-403), 7.9 μM; Gp32, 8.0 μM Bacteriophage T4 gene 32; BSA, 8.4 μM bovine serum albumin.

^b Whole yeast RNA, type XI-C (Sigma-Aldrich), when present, was used at 340 ng/μl (~1 mM in mononucleotides). This was saturating for the ATPase activity.

^c 6-aminocholestanol was dissolved in DMSO and used at 300 μM. Rows with the compound are shown shaded.

^d Mean velocity of the ATPase activity from three or more independent experiments, unless otherwise noted. The Standard deviations around the mean are shown. All reactions were done in the presence of 10% DMSO. The ATP was used at 1 mM.

^e The ATPase velocity relative to LieIF4A under optimal conditions. The standard deviations were calculated from the relative values.

*Only two independent measurements were made.

1

2 We then added a 10-fold molar excess of the purified RecA-like domain 1 (1-238 aa),
3 which we predicted would sequester the compound, reduce its effective concentration and
4 thereby partially restore the ATPase activity. Unexpectedly, RecA-like domain 1, by itself,
5 increased the apparent ATPase activity of LieIF4A in the absence of the compound (2.28
6 versus 1.89; Table 1). This could have resulted from an activation of LieIF4A by RecA-like
7 domain 1 or by an intrinsic ATPase activity of domain 1. Nevertheless, domain 1 was able to
8 restore the ATPase activity of LieIF4A to ~73% (1.67/2.28; Table 1) of the uninhibited
9 protein in the presence of 6-aminocholestanol, which was consistent with it binding and
10 sequestering the compound.

11 DEAD-box proteins are considered RNA-dependent ATPases that hydrolyze the ATP
12 in the closed configuration of the two RecA-like domains, which brings all the conserved
13 motifs in close proximity [6, 7, 12]. Therefore, the "activation" by RecA-like domain 1 was
14 surprising. We tested this by repeating the ATPase assays but with only domain 1 as a source
15 of protein. It had ~8% (0.16/1.89) of the ATPase activity of LieIF4A in the absence of RNA
16 and ~21% (0.40/1.89) in its presence; thus, the increased ATPase activity was entirely due to
17 the intrinsic ATPase activity of domain 1 (Table 1). However, this result exaggerated the
18 intrinsic activity because domain 1 was used at a ~10-fold molar excess over LieIF4A.
19 Consequently, domain 1 had only ~2.1% of the ATPase activity of LieIF4A at equimolar

1 concentrations. Under these circumstances, the compound should inhibit the RNA-dependent
2 ATPase activity of domain 1 as well, which was what we found. The activity was reduced to
3 that of the level found in the absence of RNA (Table 1). This provided further evidence that
4 6-aminocholestanol was directly interfering with RNA binding, as expected from the
5 molecular modeling.

6 It remained possible that domain 1 directly affected the activity of LieIF4A but that
7 this effect was hidden by the intrinsic ATPase activity of domain 1. We tested this with a
8 variant form of LieIF4A domain 1 (D1-GAT) that had a lysine 76 to alanine mutation in the
9 phosphate binding loop (P-loop) of motif I. This mutation has no detectable RNA-dependent
10 ATPase activity when made in the intact protein [20]. When added to LieIF4A, this mutated
11 domain 1 reduced its activity by ~29% (1.34/1.89) in the absence of the compound (Table 1).
12 However, the added compound had only a small additional effect (~4% less active;
13 1.29/1.34), which demonstrated that domain 1 was capable of efficiently sequestering the
14 molecule. This was consistent with 6-aminocholestanol binding primarily to the open (ligand-
15 free) conformation of LieIF4A, as predicted from the molecular modeling [23]. The full-
16 length LieIF4A protein in the presence of ligands would be expected to be often in the closed
17 conformation and hence less accessible to the compound. It was unclear why the GAT mutant
18 of domain 1 by itself inhibited the ATPase activity of LieIF4A, but it was possible that it
19 interfered with the formation of the catalytically active conformation of the protein. It might
20 also reduce the effective concentration of the RNA available to LieIF4A even though we used
21 a large excess of RNA.

22 Both RecA-like domains of DEAD-box proteins bind the RNA ligands. Our modeling
23 predicted that the compound would bind primarily to domain 1 but it might also bind the
24 RNA site on domain 2. We tested this by repeating the experiments with a 10-fold molar
25 excess of the purified domain 2 (239–403 aa). Domain 2 by itself reduced the ATPase activity

1 of LieIF4A by ~15% (1.60/1.89), which was about half of what we obtained with the domain
2 1 GAT mutant (Table 1). However, 6-aminocholestanol further reduced the activity, relative
3 to the wildtype activity (LieIF4A), by only an additional ~28% (85% less 57%). The net
4 result was that the compound reduced the ATPase activity of LieIF4A with domain 2
5 (LieIF4A+D2) by only ~33% (57/85), which was much less than the nearly 8-fold inhibition
6 we obtained in the absence of domain 2. Domain 2 had negligible intrinsic ATPase activity.
7 Thus, the compound also was able to bind to RecA-like domain 2 but with a lower overall
8 affinity.


9 It remained possible that 6-aminocholestanol was binding nonspecifically on multiple
10 positions of the protein that were unrelated to the RNA binding site. We tested this by adding
11 a 10-fold molar excess of bovine serum albumin (BSA), which has no known affinity for
12 nucleic acids. BSA by itself reduced the ATPase activity of LieIF4A by ~9% (1.72/1.89;
13 Table 1). However, it had no or only a slight affect on the inhibition by the compound. Thus,
14 BSA was ineffective at binding the molecule. If 6-aminocholestanol specifically interfered
15 with RNA binding, then it was possible that other nucleic acid-binding proteins would
16 sequester the compound and reduce the inhibition of the RNA-dependent ATPase activity of
17 LieIF4A. We tested this by adding a 10-fold molar excess of bacteriophage T4 gene 32
18 (Gp32), which is known to bind both single-stranded DNA and RNA, although the latter with
19 much less affinity [39]. The Gp32 protein by itself had negligible affect on the ATPase
20 activity of LieIF4A (Table 1). This result, plus the result with BSA, indicated that the more
21 pronounced inhibition with the individual RecA-like domains, in the absence of the
22 compound, was the result of more specific interactions between the separate domains and
23 LieIF4A. In contrast, the ATPase activity of LieIF4A in the presence of 300 μ M 6-
24 aminocholestanol was reduced by only ~18% (1.63/1.99) with a 10-fold molar excess of
25 Gp32. Thus, Gp32 was nearly 50% more effective than domain 2 at sequestering the

1 compound, but it was only ~85% (82%/96%) as effective as the domain 1 GAT mutant. This
2 meant that the RecA-like domain 1 had a higher affinity for the molecule, which was
3 consistent with it interacting primarily at the site we identified by molecular modeling [23].
4

5 *3.4. 6-aminocholestanol inhibits the helicase activity*

6 The preceding experiments showed that 6-aminocholestanol inhibited the ATPase
7 activity of LieIF4A by interfering with RNA and perhaps ATP binding. Therefore, it was
8 likely that the compound would inhibit the helicase activity of LieIF4A as well. We
9 previously showed that, like most DEAD-box proteins, LieIF4A was capable of displacing
10 short duplexes that were either 5' or 3' to single-stranded regions; the single-stranded RNA
11 functioned as loading sites that greatly enhance the enzymatic activity [20]. We used a variant
12 of the previous system that consisted of a 13-nucleotide-long RNA oligonucleotide, which
13 was labeled on the 5' end with ³²P, hybridized to a 45-nucleotide-long RNA template (Fig.
14 2a). This duplex was stable under the reaction conditions (Fig. 2c), and it would reform if
15 disrupted. Consequently, we added a 20-fold excess of a DNA oligonucleotide "trap" that was
16 complementary to the released ³²P-labeled RNA oligonucleotide (Fig. 2b). The resulting
17 DNA-RNA duplex migrated as smaller product during electrophoresis on a nondenaturing
18 polyacrylamide gel (Fig. 2c).

19




1
2
3 **Fig. 2.** The helicase activity of LieIF4A. (a) The helicase substrate was made by hybridizing a
4 13-nucleotide-long RNA (Hyb13) that was labeled on the 5' end with ³²P (*) with a 45-
5 nucleotide-long template RNA (K06) that was not labeled. (b) The Hyb13 released during the
6 helicase reaction was "trapped" by a complementary DNA oligonucleotide (α-Hyb1) that was
7 present at 20-fold excess of Hyb13. (c) The duplex was stable under the reaction conditions
8 in the absence of LieIF4A. However, samples heated to 90 °C formed ≥95% of the Hyb13-α-
9 Hyb1 duplex that migrated faster than the Hyb13-K06 duplex on a 15%, non-denaturing,
10 polyacrylamide gel run at 4 °C. (d) LieIF4A at 250 nM unwinds 50 nM of the duplex in the
11 presence of 1 mM ATP in a time-dependent fashion (shown in minutes). All reactions were
12 done in the presence of 10% DMSO. Ori, indicates the position of the bottom of the wells. In
13 the presence of 100 μM 6-aminocholestanol, a small amount of ³²P-Hyb13, or a complex
14 thereof, migrated as a much higher molecular weight species. (e) An equivalent unwinding

1 assay as (d) but with 1000 nM eIF4AI_{Mus}. (f) The same experiment as that shown in (d) but
2 without added ATP. (g) The same experiment as that shown in (e) but without added ATP.
3

4 We carefully calibrated the concentrations of LieIF4A and eIF4AI_{Mus} to give
5 comparable unwinding activities over the time course of the reaction in the presence of 1 mM
6 ATP and 10% DMSO. We found that 250 nM of LieIF4A and 1000 nM of eIF4AI_{Mus} gave
7 the best results (Fig. 2d and 2e). We initially tried 300 μ M 6-aminocholestanol, but we were
8 unable to detect any resulting helicase activity. Consequently, we did all the subsequent
9 experiments with 100 μ M of the compound. The compound inhibited the helicase activity of
10 both LieIF4A and eIF4AI_{Mus} but to somewhat different extents (Figs 2d and 2e). Moreover,
11 the 6-aminocholestanol caused a small amount of ³²P-Hyb13, or a complex thereof, to migrate
12 as a much higher molecular weight species. We added ~0.3% SDS to the loading buffer to
13 block protein-RNA interactions, but either the ³²P-Hyb13 interactions with the protein were
14 stabilized by the compound or the molecule promoted aggregation of the nucleic acids. We
15 quantified the bands with a phosphoimager and plotted the percentage of the duplex unwound
16 with time.

17 LieIF4A and eIF4AI_{Mus} had different reaction profiles (Fig 3a). In the absence of 6-
18 aminocholestanol, LieIF4A showed a faster initial rate than eIF4AI_{Mus} but it tended to plateau
19 with less duplex unwound. LieIF4A was used at a 4-fold lower concentration, which would
20 partially explain why eIF4AI_{Mus} showed a plateau with more duplex unwound. It also was
21 possible that LieIF4A was losing enzymatic activity more rapidly than eIF4AI_{Mus} during the
22 course of the reaction. The 6-aminocholestanol inhibited the helicase activity of both proteins.
23 Comparisons were difficult because only the initial phase of the curves could be used, which
24 contained limited data. Nevertheless, the compound reduced the helicase reaction velocities of
25 LieIF4A by 3.3- to 5.6-fold and of eIF4AI_{Mus} by 2.6- to 3.4-fold.

26




1 **Fig. 3.** Normalized mean unwinding activity of LieIF4A and eIF4AI_{Mus}. All reactions were
 2 done in the presence of 10% DMSO. The mean and standard deviations are shown for three or
 3 more independent experiments. Blue □, LieIF4A; red ○, LieIF4A with 100 μM 6-
 4 aminocholestanol; black ×, eIF4AI_{Mus}; green ◇, eIF4AI_{Mus} with 100 μM 6-aminocholestanol.
 5 (a) The unwinding activities in the presence of 1 mM ATP. (b) The unwinding activities in the
 6 absence of ATP.
 7
 8

9 We typically do parallel experiments in the absence of ATP because the high protein
 10 concentrations cause ATP-independent unwinding, probably through a mass-action effect.
 11 Indeed, we saw significant unwinding even in the absence of ATP for both LieIF4A and
 12 eIF4AI_{Mus} (Fig. 2f and 2g). Oddly, while added 6-aminocholestanol reduced this activity for
 13 LieIF4A, it actually increased the activity for eIF4AI_{Mus} in the absence of ATP. We quantified
 14 the bands with a phosphoimager and plotted the percentage of unwinding in Figure 3b. The
 15 compound reduced the activity of LieIF4A by 44% and increased the activity of eIF4AI_{Mus} by
 16 43% in an ATP-independent manner. The net result was that eIF4AI_{Mus} in the presence of 6-
 17 aminocholestanol had as much helicase activity as LieIF4A in the absence of the compound,
 18 although the latter protein was 4-fold less concentrated. It was possible that the compound
 19 stabilized protein-RNA interactions that promoted the ATP-independent unwinding of
 20 eIF4AI_{Mus}. This would not be true for LieIF4A because our modeling studies indicated that
 21 the primary binding sites existed in the open complex that would lack helicase activity. Thus,

1 LieIF4A and eIF4AI_{Mus} appear to have different binding sites and to behave differently to the
2 presence of the compound.

3 As noted above, it was possible that the DMSO used to solubilize the compounds
4 affected the enzymatic properties of the proteins. This would account for why the Michaelis-
5 Menten values we obtained for the RNA-dependent ATPase assays showed 2-fold higher
6 binding affinities and ATP hydrolysis rates for LieIF4A than previously determined [20]. We
7 repeated the helicase experiments of LieIF4A and eIF4IA_{Mus} with the K06-Hyb13 RNA
8 duplex in the presence of 1 mM ATP and the presence or absence of 10% DMSO
9 (Supplementary data Fig. S1) and quantified the results in Figure 4. We found that the DMSO
10 significantly enhanced the unwinding reaction of both LieIF4A and eIF4AI_{Mus}, but that the
11 increased activity was more pronounced for LieIF4A. DMSO is a polar aprotic solvent that is
12 capable of dissolving both polar and nonpolar compounds [40]. It may have destabilized the
13 RNA duplex, but DMSO is also known to enhance the flexibility of proteins and to enhance
14 or inhibit enzymatic activities [40-43].

15



16


17 **Fig. 4.** Normalized mean unwinding activity of LieIF4A and eIF4AI_{Mus} ±10% DMSO.
18 Reactions were done in the presence or absence of 10% DMSO and 1 mM ATP. The mean
19 and standard deviations are shown for three or more independent experiments. Blue □,
20 LieIF4A; red o, LieIF4A with 10% DMSO; black x, eIF4AI_{Mus}; green ◇, eIF4AI_{Mus} with 10%
21 DMSO.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

3.5. Molecular modeling, dynamics and docking simulations

The experimental results we obtained indicated that there were additional binding sites on LieIF4A that were not previously taken into account [23]. Therefore, we re-analyzed our molecular dynamics through an exhaustive search for cavities and pockets on the protein surface in its open and closed conformations, and we re-performed docking simulations of 6- α -aminocholestanol on the identified pockets. We undertook similar analyses on the solved crystal structure of eIF4A_{Mus}, and as controls on the solved crystal structures of Gp32 and BSA.

The identified cavities were then examined for their potential to be effective binding sites for 6- α -aminocholestanol. A total of 60 cavities were identified that mostly appeared either on the open or closed forms of LieIF4A, but eleven of these pockets were detected on both states. We further investigated the distribution of the docking scores obtained on LieIF4A for each of the 60 pockets. Only eighteen out of the 60 pockets demonstrated at least one binding mode of the compound with a negative docking score, and they were retained for further analyses. Of these eighteen, only five demonstrated significant docking scores of -6 kcal/mole or less (Table 2) [33]. Three of these pockets (P11, P19, P29; Fig. 5a–5c) were found only on the open conformation and two (P26, P39; Fig. 5d, 5e) were only on the closed form. The pockets P19, P26, P29 and P39 were in the interdomain cleft between the two RecA-like domains while P11 was in the previously identified pocket in domain 1 [23]. The docked compounds in all the identified pockets made significant interactions with the conserved motifs involved in ligand binding, and many of these interactions were overlapping in the different pockets (Fig. 5, 6).



1
2 **Fig. 5.** Interactions of 6- α -aminocholestanol on the identified pockets of LieIF4A and
3 eIF4A1Mus as determined with LigPlot+. Interactions involving residues in conserved motifs
4 are as indicated. The red "brushes" represent van der Waals force interactions and the dotted
5 green lines represent hydrogen bonds. (a) The compound bound in pocket P11 of the open
6 form of LieIF4A. (b) The compound in pocket P19 of the open form of LieIF4A. (c) The
7 compound in pocket P29 of the open form of LieIF4A. (d) The compound bound in pocket
8 P26 of the closed form of LieIF4A. (e) The compound in pocket P39 of the closed form of
9 LieIF4A. (f) The compound in pocket P14 of the open form of eIF4A1Mus.
10



1
 2 **Fig. 6.** Location of the interactions of 6- α -aminocholestanol on LieIF4A and eIF4AI_{Mus}. The
 3 linker region between RecA-like domain 1 and domain 2 is indicated with a dotted line.
 4 Interactions of P11 LieIF4A, P19 LieIF4A, P26 LieIF4A and P14 DDX2A (eIF4AI_{Mus})
 5 involve the "open" conformation. Interactions of P29 LieIF4A and P39 LieIF4A involve the
 6 "closed" conformation. The position of the LieIF4A GAT mutation of domain 1 is as shown.
 7

8 We conducted similar cavity search and docking simulations on the mammalian
 9 ortholog eIF4AI (DDX2A), and we obtained results that indicated a unique potential binding
 10 site with a significant binding energy (P14; Fig. 5f, Fig. 6; Table 2). It was well below the
 11 cutoff value of -6 kcal/mole. Pocket P14 was located in the central part of the inter-domain
 12 cleft. The interactions of its amino acids overlapped with those of the four pockets of the
 13 inter-domain cleft of LieIF4A (Fig. 5, 6). The docking score for eIF4AI P14 was comparable
 14 to those obtained for the LieIF4A pockets (Table 2).
 15

Table 2. Docking scores and positions of 6- α -aminocholestanol on proteins.

Protein	Form	Pocket	Score ^a	Interact. ^b	%D1 ^c	%Link. ^c	%D2 ^c
LieIF4A	open	P11	-9.16	12	100	0	0
LieIF4A	open	P19	-6.35	10	0	30	70
LieIF4A	open	P29	-10.14	15	60	6.7	33.3
LieIF4A	closed	P26	-9.04	13	76.9	7.7	15.4
LieIF4A	closed	P39	-9.58	11	63.6	9.1	27.3
DDX2A	open	P14	-9.19	10	0	10	90
Gp32	NA ^d	P17	-4.47	10	NA	NA	NA
BSA	NA	P12	-10.7	11	NA	NA	NA
BSA	NA	P18	-8.24	16	NA	NA	NA
BSA	NA	P32	-8.22	12	NA	NA	NA
BSA	NA	P42	-7.56	15	NA	NA	NA

^a The scores represent the calculated binding energies in kcal/mole.

^b The interactions represent the number of amino acids that form hydrogen bonds and van der Waals force interactions with the compound.

^c The fraction of interactions that occur in RecA-like domain 1, RecA-like domain 2 or in the linker region between the two domains.

^d Not applicable.

1

2 As a control, we made cavity search and simulations on the solved crystal structures of
3 bacteriophage T4 Gp32 and BSA. The former was an effective competitor for the compound
4 while the latter was not. We obtained a single binding site on Gp32 with negative binding
5 energy that was located on the putative nucleic acids binding site, but it was significantly
6 above the cutoff value of -6 kcal/mole (P14; Supplementary data Fig. S2, Table 2). However,
7 the solved crystal structure was missing 27.6% of its amino acids; consequently there may
8 have been other sites on the full-length protein that were not detected by our molecular
9 simulations. Moreover, the missing amino terminus was close to the binding site, and it might
10 have enhanced the affinity for the compound. Hence, proteins with nucleic acids binding sites
11 are potential targets for the compound, and therefore it is important to take into consideration
12 such off-target effects in screening for more specific inhibitors.

13 In contrast, we found four binding pockets on BSA with binding energies that were
14 well below the cutoff of -6 kcal/mole (Table 2). We used both chains of the solved crystal
15 structure but only one (P32) of the four pockets was found on both chains. Notably, P32 made
16 no specific hydrogen bonds with the ligand. Chain B was missing A583 and A584, and both

1 chains lacked the first 26 amino-terminal residues. Both chains were largely superimposable,
2 and the missing amino-acid residues were far from the identified binding pockets. This
3 suggests that there were subtle differences in the structures, and that the pockets identified
4 might not be representative of those found in solution. Moreover, the DMSO in the solution
5 may have more profound effects on the conformation of BSA than for the other proteins.
6 Indeed, it is known that BSA becomes partially denatured in DMSO [44].

7

8 **4. Discussion**

9 Trypanosomatids and many fungi have an essential requirement for ergosterol, which
10 is a 24-alkyl sterol that serves a similar role to cholesterol in membrane fluidity; it is not
11 utilized in animals [45, 46]. As a consequence, the biosynthetic pathway of ergosterol is a
12 common target for antifungal and anti-protozoan drugs [47, 48]. Among these candidate
13 drugs are the epimers 6- α/β -aminocholestanol and the related 7- α/β -aminocholestanol that
14 target the $\Delta^8 \rightarrow \Delta^7$ -sterol isomerase [24, 49]. However, we independently found through
15 molecular modeling, molecular dynamics and docking simulations that 6-aminocholestanol
16 could target the *L. infantum* LieIF4A protein, which is a probable ortholog of the translation-
17 initiation factor eIF4A [20, 23]. Moreover, it shows structural similarity to the previously
18 characterized hippuristanol that is an allosteric inhibitor of RNA binding in eukaryotic
19 eIF4A-like proteins that locks the RecA-like domains in a nonproductive closed conformation
20 [19].

21 We find that 6-aminocholestanol competitively inhibits both ATP and RNA binding to
22 LieIF4A, and by doing so it inhibits the helicase activity of the protein as well. Our molecular
23 dynamics, cavity analysis and docking simulations and competition assays with the individual
24 RecA-like domains indicate that there are multiple binding sites for the compound on
25 LieIF4A. Moreover, all of the identified binding pockets involve interactions with the

1 conserved motifs needed for ligand binding and enzymatic activities. With the exception of
2 pocket P19, these interactions involve residues that are predominately located on RecA-like
3 domain 1 (Table 2, Fig. 5, 6). However, only pocket P11 in the open conformation is found
4 exclusively on domain 1, and this appears to be the primary binding site of the compound.
5 Although not unique, the preferential binding of 6-aminocholestanol at this site demonstrates
6 a degree of specificity in the binding.

7 In contrast, pocket P19 was exclusively on RecA-like domain 2 and the linker region
8 between domains. It has a relatively weak docking score (Table 2) and the domain 2 fragment
9 used in the competition experiments is missing the linker region; nevertheless, the D2
10 fragment is about 70% as effective as D1-GAT in sequestering the 6-aminocholestanol (after
11 normalizing for the inhibitory effects of the isolated domains by themselves; Table 2). Hence,
12 molecular dynamics and docking simulations correctly pointed to the existence of multiple
13 plausible binding sites for the compound. Nevertheless, the docking scores we obtained are
14 not closely representative of the actual binding affinities. This is not uncommon for docking
15 on modeled structures. Moreover, our molecular dynamics simulations did not take into the
16 account the effects of DMSO, which probably increased the protein flexibility.

17 The best docking score obtained is with pocket P29 in the open conformation. It
18 makes extensive interactions with the Q motif, which is important for adenine recognition
19 [50]. However, this pocket lacked the interactions with the critical 6-position amino group,
20 which conferred ~11-fold higher inhibition than the equivalent compound with 6-position
21 keto [23]. Consequently, it may have played a secondary role in the inhibitory effects of the
22 compound. Likewise, it is unclear from our experiments what role(s) pockets P26 and P39
23 may play in the closed conformation (Fig. 5d, 5e). However, it should be noted that many of
24 the pockets involve interactions with the same amino acids (Fig. 6).

1 Our cavity analysis and docking simulations revealed only a single binding pocket on
2 the open conformation of eIF4AI_{Mus}, which was based on the solved crystal structure (Fig.
3 5f). Molecular modeling, molecular dynamics and docking simulations of the closed
4 conformation might reveal additional sites. Nevertheless, the binding site we found is similar
5 to that proposed for the allosteric inhibitor hippuristanol, which is thought to lock the RecA-
6 like domains into an altered closed conformation [19]. We find that 6-aminocholestanol
7 significantly enhances the ATP-independent unwinding activity of eIF4AI_{Mus}, which suggests
8 that it too can lock the protein in an aberrantly closed conformation. Although hippuristanol
9 and 6-aminocholestanol are both hydroxycholestanol derivatives, there are significant
10 differences in their structures. Thus, in the future it may be useful to screen from a wide
11 variety of hydroxycholestanol derivatives to select for those most specific for the eIF4A
12 protein of the organism of interest.

13 The 6-aminocholestanol epimers were previously identified as antifungal agents
14 because they could interfere with ergosterol biosynthesis [24]. Here, we find that they bind to
15 and inhibit DEAD-box proteins as well. Nevertheless, these compounds interact with proteins
16 in different ways and with different affects on their enzymology in accordance with previous
17 results [23]. We demonstrated that they differently affect the mammalian and *Leishmania*
18 proteins due to their different binding sites and affinities. Moreover, we note the occurrence
19 of multiple compound-binding sites with major one(s) on LieIF4A RecA-like domain 1. We
20 find it encouraging that the observation that 6-aminocholestanol binds certain sites with a
21 higher affinity than others demonstrates a degree of specificity that can potentially be
22 optimized by modifying the functionalities on the chemical backbone of the
23 hydroxycholestanol. This will be facilitated once we have a solved crystal structure of
24 LieIF4A with the bound compound, which is work currently in progress. Therefore, it is
25 possible to screen for derivatives of these agents that selectively target DEAD-box proteins

1 from different organisms even when implicated in the same biological process. We hope that
2 this work will foster further research in this domain.

3

4 **Conflict of interest**

5 The authors have no conflicts of interest to declare.

6

7 **Acknowledgments**

8 We thank Patrick Linder, Centre Médical Universitaire, Geneva, Switzerland, for the
9 eIF4AI_{Mus} clone. The 6-aminocholestanol was a gift from Dr. Leila el Kihel, Centre d'Etudes
10 et de Recherche sur le Médicament de Normandie (CERMN), UFR des Sciences
11 Pharmaceutiques, Université de Caen de Basse-Normandie, France, for the minimal costs of
12 shipping fees. We thank Damien Monet for his assistance in the cavity generation and
13 analyses. This work was supported by the Centre National de la Recherche Scientifique, by
14 the HelicaRN [2010 BLAN 1503 01] and HeliDEAD grants [ANR-13-BSV8-0009-01] from
15 the Agence Nationale de la Recherche, and by the Initiative d'Excellence program from the
16 French State [Grant DYNAMO, ANR-11-LABX-0011-01] to NKT. This work received
17 financial support from the Pasteur Institute Transversal Research Program (grant PTR426),
18 and partially from the Ministry of Higher Education and Research in Tunisia (LR11IPT04 &
19 LR16IPT04) to IG. EHS received support from the UNESCO-L'Oréal, "For Women in
20 Science," international fellowship and the Institut Pasteur International Network (Calmette
21 and Yersin programme).

22

23 **References**

24

25 [1] J. Alvar, I.D. Velez, C. Bern, M. Herrero, P. Desjeux, J. Cano, J. Jannin, M. den Boer,
26 Leishmaniasis worldwide and global estimates of its incidence, PLoS One 7(5) (2012)
27 e35671. <https://doi.org/10.1371/journal.pone.0035671>.

- 1 [2] N. Singh, B.B. Mishra, S. Bajpai, R.K. Singh, V.K. Tiwari, Natural product based leads
2 to fight against leishmaniasis, *Bioorg. Med. Chem.* 22(1) (2014) 18-45.
3 <https://doi.org/10.1016/j.bmc.2013.11.048>.
- 4 [3] S. Burza, S.L. Croft, M. Boelaert, Leishmaniasis, *Lancet* 392(10151) (2018) 951-970.
5 [https://doi.org/10.1016/s0140-6736\(18\)31204-2](https://doi.org/10.1016/s0140-6736(18)31204-2).
- 6 [4] M.S. Duthie, V.S. Raman, F.M. Piazza, S.G. Reed, The development and clinical
7 evaluation of second-generation leishmaniasis vaccines, *Vaccine* 30(2) (2012) 134-141.
8 <https://doi.org/10.1016/j.vaccine.2011.11.005>.
- 9 [5] O. Cordin, J. Banroques, N.K. Tanner, P. Linder, The DEAD-box protein family of
10 RNA helicases, *Gene* 367 (2006) 17-37. <https://doi.org/10.1016/j.gene.2005.10.019>.
- 11 [6] P. Linder, E. Jankowsky, From unwinding to clamping - the DEAD box RNA helicase
12 family, *Nat. Rev. Mol. Cell. Biol.* 12(8) (2011) 505-516.
13 <https://doi.org/10.1038/nrm3154>.
- 14 [7] N.K. Tanner, P. Linder, DExD/H box RNA helicases: from generic motors to specific
15 dissociation functions, *Mol. Cell* 8(2) (2001) 251-262.
- 16 [8] M. Senissar, A. Le Saux, N. Belgareh-Touze, C. Adam, J. Banroques, N.K. Tanner, The
17 DEAD-box helicase Ded1 from yeast is an mRNP cap-associated protein that shuttles
18 between the cytoplasm and nucleus, *Nucleic Acids Res.* 42(15) (2014) 10005-10022.
19 <https://doi.org/10.1093/nar/gku584>.
- 20 [9] J. de la Cruz, D. Kressler, P. Linder, Unwinding RNA in *Saccharomyces cerevisiae*:
21 DEAD-box proteins and related families, *Trends Biochem. Sci.* 24(5) (1999) 192-198.
- 22 [10] M. Abdelhaleem, L. Maltais, H. Wain, The human DDX and DHX gene families of
23 putative RNA helicases, *Genomics* 81(6) (2003) 618-622.
- 24 [11] P.R. Gargantini, H.D. Lujan, C.A. Pereira, *In silico* analysis of trypanosomatids'
25 helicases, *FEMS Microbiol. Lett.* 335(2) (2012) 123-129.
26 <https://doi.org/10.1111/j.1574-6968.2012.02644.x>.
- 27 [12] P. Schutz, T. Karlberg, S. van den Berg, R. Collins, L. Lehtio, M. Hogbom, L.
28 Holmberg-Schiavone, W. Tempel, H.W. Park, M. Hammarstrom, M. Moche, A.G.
29 Thorsell, H. Schuler, Comparative structural analysis of human DEAD-box RNA
30 helicases, *PLoS One* 5(9) (2010). <https://doi.org/10.1371/journal.pone.0012791>.
- 31 [13] L.A. Marchat, S.I. Arzola-Rodriguez, O. Hernandez-de la Cruz, I. Lopez-Rosas, C.
32 Lopez-Camarillo, DEAD/DExH-Box RNA Helicases in Selected Human Parasites,
33 *Korean J. Parasitol.* 53(5) (2015) 583-595. <https://doi.org/10.3347/kjp.2015.53.5.583>.
- 34 [14] W.R. Shadrack, J. Ndjomou, R. Kolli, S. Mukherjee, A.M. Hanson, D.N. Frick,
35 Discovering new medicines targeting helicases: challenges and recent progress, *J.*
36 *Biomol. Screen.* 18(7) (2013) 761-781. <https://doi.org/10.1177/1087057113482586>.
- 37 [15] R. Cencic, J. Pelletier, Throwing a monkey wrench in the motor: targeting DExH/D box
38 proteins with small molecule inhibitors, *Biochim. Biophys. Acta* 1829(8) (2013) 894-
39 903. <https://doi.org/10.1016/j.bbagr.2013.01.008>.

- 1 [16] L. Steimer, D. Klostermeier, RNA helicases in infection and disease, RNA Biol. 9(6)
2 (2012) 751-771. <https://doi.org/10.4161/rna.20090>.
- 3 [17] J. Chu, J. Pelletier, Targeting the eIF4A RNA helicase as an anti-neoplastic approach,
4 Biochim. Biophys. Acta 1849(7) (2015) 781-791.
5 <https://doi.org/10.1016/j.bbagr.2014.09.006>.
- 6 [18] C.H. Chao, L.F. Huang, Y.L. Yang, J.H. Su, G.H. Wang, M.Y. Chiang, Y.C. Wu, C.F.
7 Dai, J.H. Sheu, Polyoxygenated steroids from the gorgonian *Isis hippuris*, J. Nat. Prod.
8 68(6) (2005) 880-885. <https://doi.org/10.1021/np050033y>.
- 9 [19] R. Cencic, J. Pelletier, Hippuristanol - A potent steroid inhibitor of eukaryotic initiation
10 factor 4A, Translation (Austin) 4(1) (2016) e1137381.
11 <https://doi.org/10.1080/21690731.2015.1137381>.
- 12 [20] M. Barhoumi, N.K. Tanner, J. Banroques, P. Linder, I. Guizani, *Leishmania infantum*
13 LeIF protein is an ATP-dependent RNA helicase and an eIF4A-like factor that inhibits
14 translation in yeast, FEBS J. 273(22) (2006) 5086-5100. <https://doi.org/10.1111/j.1742-4658.2006.05506.x>.
- 16 [21] R. Dhaliya, N. Marinsek, C.R. Reis, R. Katz, J.R. Muniz, N. Standart, M. Carrington,
17 O.P. de Melo Neto, The two eIF4A helicases in *Trypanosoma brucei* are functionally
18 distinct, Nucleic Acids Res. 34(9) (2006) 2495-2507.
19 <https://doi.org/10.1093/nar/gkl290>.
- 20 [22] R. Dhaliya, C.R. Reis, E.R. Freire, P.O. Rocha, R. Katz, J.R. Muniz, N. Standart, O.P. de
21 Melo Neto, Translation initiation in *Leishmania major*: characterisation of multiple
22 eIF4F subunit homologues, Mol. Biochem. Parasitol. 140(1) (2005) 23-41.
23 <https://doi.org/10.1016/j.molbiopara.2004.12.001>.
- 24 [23] E. Harigua-Souiai, Y.Z. Abdelkrim, I. Bassoumi-Jamoussi, O. Zakraoui, G. Bouvier, K.
25 Essafi-Benkhadir, J. Banroques, N. Desdouts, H. Munier-Lehmann, M. Barhoumi,
26 N.K. Tanner, M. Nilges, A. Blondel, I. Guizani, Identification of novel leishmanicidal
27 molecules by virtual and biochemical screenings targeting *Leishmania* eukaryotic
28 initiation factor 4A, PLoS Negl. Trop. Dis. 12(1) (2018) e0006160.
29 <https://doi.org/10.1371/journal.pntd.0006160>.
- 30 [24] P. Beuchet, L. el Kihel, M. Dherbomez, G. Charles, Y. Letourneux, Synthesis of
31 6(alpha, beta)-aminocholestanols as ergosterol biosynthesis inhibitors, Bioorg. Med.
32 Chem. Lett. 8(24) (1998) 3627-3630.
- 33 [25] M. Barhoumi, A. Garnaoui, B. Kaabi, N.K. Tanner, I. Guizani, *Leishmania infantum*
34 LeIF and its recombinant polypeptides modulate interleukin IL-12p70, IL-10 and
35 tumour necrosis factor-alpha production by human monocytes, Parasite Immunol.
36 33(10) (2011) 583-588. <https://doi.org/10.1111/j.1365-3024.2011.01320.x>.
- 37 [26] A. Prat, S.R. Schmid, P. Buser, S. Blum, H. Trachsel, P.J. Nielsen, P. Linder,
38 Expression of translation initiation factor 4A from yeast and mouse in *Saccharomyces*
39 *cerevisiae*, Biochim. Biophys. Acta 1050(1-3) (1990) 140-145.
- 40 [27] J. Banroques, M. Doere, M. Dreyfus, P. Linder, N.K. Tanner, Motif III in superfamily 2
41 "helicases" helps convert the binding energy of ATP into a high-affinity RNA binding

- 1 site in the yeast DEAD-box protein Ded1, J. Mol. Biol. 396(4) (2010) 949-966.
2 <https://doi.org/10.1016/j.jmb.2009.12.025>.
- 3 [28] O. Cordin, N.K. Tanner, M. Doere, P. Linder, J. Banroques, The newly discovered Q
4 motif of DEAD-box RNA helicases regulates RNA-binding and helicase activity,
5 EMBO J. 23(13) (2004) 2478-2487. <https://doi.org/10.1038/sj.emboj.7600272>.
- 6 [29] D.H. Turner, N. Sugimoto, S.M. Freier, RNA structure prediction, Annu. Rev. Biophys.
7 Biophys. Chem. 17 (1988) 167-192.
8 <https://doi.org/10.1146/annurev.bb.17.060188.001123>.
- 9 [30] B. Lee, F.M. Richards, The interpretation of protein structures: estimation of static
10 accessibility, J. Mol. Biol. 55(3) (1971) 379-400.
- 11 [31] N. Desdouts, M. Nilges, A. Blondel, Principal Component Analysis reveals correlation
12 of cavities evolution and functional motions in proteins, J. Mol. Graph. Model. 55
13 (2015) 13-24. <https://doi.org/10.1016/j.jmglm.2014.10.011>.
- 14 [32] G.M. Morris, R. Huey, W. Lindstrom, M.F. Sanner, R.K. Belew, D.S. Goodsell, A.J.
15 Olson, AutoDock4 and AutoDockTools4: Automated docking with selective receptor
16 flexibility, J. Comput. Chem. 30(16) (2009) 2785-2791.
17 <https://doi.org/10.1002/jcc.21256>.
- 18 [33] S. Shityakov, C. Forster, *In silico* predictive model to determine vector-mediated
19 transport properties for the blood-brain barrier choline transporter, Adv. Appl.
20 Bioinform. Chem. 7 (2014) 23-36. <https://doi.org/10.2147/aabc.s63749>.
- 21 [34] R.A. Laskowski, M.B. Swindells, LigPlot+: multiple ligand-protein interaction
22 diagrams for drug discovery, J. Chem. Inf. Model. 51(10) (2011) 2778-2786.
23 <https://doi.org/10.1021/ci200227u>.
- 24 [35] N. Guex, M.C. Peitsch, SWISS-MODEL and the Swiss-PdbViewer: an environment for
25 comparative protein modeling, Electrophoresis 18(15) (1997) 2714-2723.
26 <https://doi.org/10.1002/elps.1150181505>.
- 27 [36] M. Dixon, The determination of enzyme inhibitor constants, Biochem. J. 55(1) (1953)
28 170-171.
- 29 [37] J.R. Lorsch, D. Herschlag, The DEAD box protein eIF4A. 1. A minimal kinetic and
30 thermodynamic framework reveals coupled binding of RNA and nucleotide,
31 Biochemistry 37(8) (1998) 2180-2193. <https://doi.org/10.1021/bi972430g>.
- 32 [38] S.P. Ryder, M.I. Recht, J.R. Williamson, Quantitative analysis of protein-RNA
33 interactions by gel mobility shift, Methods Mol. Biol. 488 (2008) 99-115.
34 https://doi.org/10.1007/978-1-60327-475-3_7.
- 35 [39] G. Lemaire, L. Gold, M. Yarus, Autogenous translational repression of bacteriophage
36 T4 gene 32 expression *in vitro*, J. Mol. Biol. 126(1) (1978) 73-90.
- 37 [40] C.F. Brayton, Dimethyl sulfoxide (DMSO): a review, Cornell Vet. 76(1) (1986) 61-90.

- 1 [41] C. Monder, Discussion: effect of DMSO on enzyme activity, *Ann. N. Y. Acad. Sci.*
2 141(1) (1967) 300-301.
- 3 [42] D.H. Rammler, The effect of DMSO on several enzyme systems, *Ann. N. Y. Acad. Sci.*
4 141(1) (1967) 291-299.
- 5 [43] D.H. Rammler, A. Zaffaroni, Biological implications of DMSO based on a review of its
6 chemical properties, *Ann. N. Y. Acad. Sci.* 141(1) (1967) 13-23.
- 7 [44] A. Pabbathi, S. Patra, A. Samanta, Structural transformation of bovine serum albumin
8 induced by dimethyl sulfoxide and probed by fluorescence correlation spectroscopy and
9 additional methods, *Chemphyschem* 14(11) (2013) 2441-2449.
10 <https://doi.org/10.1002/cphc.201300313>.
- 11 [45] S. Dupont, G. Lemetais, T. Ferreira, P. Cayot, P. Gervais, L. Beney, Ergosterol
12 biosynthesis: a fungal pathway for life on land?, *Evolution* 66(9) (2012) 2961-2968.
13 <https://doi.org/10.1111/j.1558-5646.2012.01667.x>.
- 14 [46] H. Dixon, C.D. Ginger, J. Williamson, Trypanosome sterols and their metabolic origins,
15 *Comp. Biochem. Physiol. B* 41(1) (1972) 1-18.
- 16 [47] S.T. de Macedo-Silva, W. de Souza, J.C. Rodrigues, Sterol Biosynthesis Pathway as an
17 Alternative for the Anti-Protozoan Parasite Chemotherapy, *Curr. Med. Chem.* 22(18)
18 (2015) 2186-2198.
- 19 [48] D.G. Sant, S.G. Tupe, C.V. Ramana, M.V. Deshpande, Fungal cell membrane-
20 promising drug target for antifungal therapy, *J. Appl. Microbiol.* 121(6) (2016) 1498-
21 1510. <https://doi.org/10.1111/jam.13301>.
- 22 [49] S. Fouace, L. El kihel, M. Dherbomez, Y. Letourneux, Stereoselective synthesis of 7
23 alpha- and 7 beta-amincholestanol as potent fungicidal drugs, *Bioorg. Med. Chem.*
24 *Lett.* 11(23) (2001) 3011-3014.
- 25 [50] N.K. Tanner, O. Cordin, J. Banroques, M. Doere, P. Linder, The Q motif: a newly
26 identified motif in DEAD box helicases may regulate ATP binding and hydrolysis, *Mol.*
27 *Cell* 11(1) (2003) 127-138.

28